194 related articles for article (PubMed ID: 22101269)
1. TGFβ-induced c-Myb affects the expression of EMT-associated genes and promotes invasion of ER+ breast cancer cells.
Cesi V; Casciati A; Sesti F; Tanno B; Calabretta B; Raschellà G
Cell Cycle; 2011 Dec; 10(23):4149-61. PubMed ID: 22101269
[TBL] [Abstract][Full Text] [Related]
2. Activation of miR200 by c-Myb depends on ZEB1 expression and miR200 promoter methylation.
Pieraccioli M; Imbastari F; Antonov A; Melino G; Raschellà G
Cell Cycle; 2013 Jul; 12(14):2309-20. PubMed ID: 24067373
[TBL] [Abstract][Full Text] [Related]
3. Direct repression of MYB by ZEB1 suppresses proliferation and epithelial gene expression during epithelial-to-mesenchymal transition of breast cancer cells.
Hugo HJ; Pereira L; Suryadinata R; Drabsch Y; Gonda TJ; Gunasinghe NP; Pinto C; Soo ET; van Denderen BJ; Hill P; Ramsay RG; Sarcevic B; Newgreen DF; Thompson EW
Breast Cancer Res; 2013 Nov; 15(6):R113. PubMed ID: 24283570
[TBL] [Abstract][Full Text] [Related]
4. PARP3 controls TGFβ and ROS driven epithelial-to-mesenchymal transition and stemness by stimulating a TG2-Snail-E-cadherin axis.
Karicheva O; Rodriguez-Vargas JM; Wadier N; Martin-Hernandez K; Vauchelles R; Magroun N; Tissier A; Schreiber V; Dantzer F
Oncotarget; 2016 Sep; 7(39):64109-64123. PubMed ID: 27579892
[TBL] [Abstract][Full Text] [Related]
5. ShRNA-mediated gene silencing of MTA1 influenced on protein expression of ER alpha, MMP-9, CyclinD1 and invasiveness, proliferation in breast cancer cell lines MDA-MB-231 and MCF-7 in vitro.
Jiang Q; Zhang H; Zhang P
J Exp Clin Cancer Res; 2011 May; 30(1):60. PubMed ID: 21595884
[TBL] [Abstract][Full Text] [Related]
6. MiR-155-mediated loss of C/EBPβ shifts the TGF-β response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer.
Johansson J; Berg T; Kurzejamska E; Pang MF; Tabor V; Jansson M; Roswall P; Pietras K; Sund M; Religa P; Fuxe J
Oncogene; 2013 Dec; 32(50):5614-24. PubMed ID: 23955085
[TBL] [Abstract][Full Text] [Related]
7. Benzyl isothiocyanate inhibits epithelial-mesenchymal transition in cultured and xenografted human breast cancer cells.
Sehrawat A; Singh SV
Cancer Prev Res (Phila); 2011 Jul; 4(7):1107-17. PubMed ID: 21464039
[TBL] [Abstract][Full Text] [Related]
8. CDK9 inhibitors selectively target estrogen receptor-positive breast cancer cells through combined inhibition of MYB and MCL-1 expression.
Mitra P; Yang RM; Sutton J; Ramsay RG; Gonda TJ
Oncotarget; 2016 Feb; 7(8):9069-83. PubMed ID: 26812885
[TBL] [Abstract][Full Text] [Related]
9. miR-200 affects tamoxifen resistance in breast cancer cells through regulation of MYB.
Gao Y; Zhang W; Liu C; Li G
Sci Rep; 2019 Dec; 9(1):18844. PubMed ID: 31827114
[TBL] [Abstract][Full Text] [Related]
10. Expression of Slug is regulated by c-Myb and is required for invasion and bone marrow homing of cancer cells of different origin.
Tanno B; Sesti F; Cesi V; Bossi G; Ferrari-Amorotti G; Bussolari R; Tirindelli D; Calabretta B; Raschellà G
J Biol Chem; 2010 Sep; 285(38):29434-45. PubMed ID: 20622260
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanism of miR-153 inhibiting migration, invasion and epithelial-mesenchymal transition of breast cancer by regulating transforming growth factor beta (TGF-β) signaling pathway.
Wang J; Liang S; Duan X
J Cell Biochem; 2019 Jun; 120(6):9539-9546. PubMed ID: 30525231
[TBL] [Abstract][Full Text] [Related]
12. Fucoidan induces changes in the epithelial to mesenchymal transition and decreases metastasis by enhancing ubiquitin-dependent TGFβ receptor degradation in breast cancer.
Hsu HY; Lin TY; Hwang PA; Tseng LM; Chen RH; Tsao SM; Hsu J
Carcinogenesis; 2013 Apr; 34(4):874-84. PubMed ID: 23275155
[TBL] [Abstract][Full Text] [Related]
13. FUT8 promotes breast cancer cell invasiveness by remodeling TGF-β receptor core fucosylation.
Tu CF; Wu MY; Lin YC; Kannagi R; Yang RB
Breast Cancer Res; 2017 Oct; 19(1):111. PubMed ID: 28982386
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-150-5p promotes cell motility by inhibiting c-Myb-mediated Slug suppression and is a prognostic biomarker for recurrent ovarian cancer.
Tung CH; Kuo LW; Huang MF; Wu YY; Tsai YT; Wu JE; Hsu KF; Chen YL; Hong TM
Oncogene; 2020 Jan; 39(4):862-876. PubMed ID: 31570789
[TBL] [Abstract][Full Text] [Related]
15. Posttranscriptional regulation of the c-myb proto-oncogene in estrogen receptor-positive breast cancer cells.
Gudas JM; Klein RC; Oka M; Cowan KH
Clin Cancer Res; 1995 Feb; 1(2):235-43. PubMed ID: 9815978
[TBL] [Abstract][Full Text] [Related]
16. Establishment of twist-1 and TGFBR2 as direct targets of microRNA-20a in mesenchymal to epithelial transition of breast cancer cell-line MDA-MB-231.
De S; Das S; Mukherjee S; Das S; Sengupta Bandyopadhyay S
Exp Cell Res; 2017 Dec; 361(1):85-92. PubMed ID: 28987542
[TBL] [Abstract][Full Text] [Related]
17. Oncofetal H19 RNA promotes tumor metastasis.
Matouk IJ; Raveh E; Abu-lail R; Mezan S; Gilon M; Gershtain E; Birman T; Gallula J; Schneider T; Barkali M; Richler C; Fellig Y; Sorin V; Hubert A; Hochberg A; Czerniak A
Biochim Biophys Acta; 2014 Jul; 1843(7):1414-26. PubMed ID: 24703882
[TBL] [Abstract][Full Text] [Related]
18. Specific interactions between Smad proteins and AP-1 components determine TGFβ-induced breast cancer cell invasion.
Sundqvist A; Zieba A; Vasilaki E; Herrera Hidalgo C; Söderberg O; Koinuma D; Miyazono K; Heldin CH; Landegren U; Ten Dijke P; van Dam H
Oncogene; 2013 Aug; 32(31):3606-15. PubMed ID: 22926518
[TBL] [Abstract][Full Text] [Related]
19. Narasin inhibits tumor metastasis and growth of ERα‑positive breast cancer cells by inactivation of the TGF‑β/SMAD3 and IL‑6/STAT3 signaling pathways.
Chen J; Huang X; Li N; Liu B; Ma Z; Ling J; Yang W; Li T
Mol Med Rep; 2020 Dec; 22(6):5113-5124. PubMed ID: 33174044
[TBL] [Abstract][Full Text] [Related]
20. Foxf2 plays a dual role during transforming growth factor beta-induced epithelial to mesenchymal transition by promoting apoptosis yet enabling cell junction dissolution and migration.
Meyer-Schaller N; Heck C; Tiede S; Yilmaz M; Christofori G
Breast Cancer Res; 2018 Oct; 20(1):118. PubMed ID: 30285803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
